57 participants
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-11
- Start Date:
- 2023-05-18
- Completion:
- 2027-03-31
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Locally Advanced Triple-Negative Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
Interventions
- DRUG
- PROCEDURE
- BIOLOGICAL
No Results Yet